Lasmiditan and Phenergan (Promethazine Tablets)
Determining the interaction of Lasmiditan and Phenergan (Promethazine Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions. Patients treated with lasmiditan are at risk of CNS depression, including dizziness and sedation, as well as driving impairment. In clinical studies, dizziness and sedation were reported in up to 17% and 7%, respectively, of patients receiving lasmiditan, and dizziness was the most common adverse event resulting in discontinuation (greater than 2%). In a computer-based driving study, a significant, dose-dependent impairment of subjects' ability to drive was observed with single 50, 100, and 200 mg lasmiditan doses at 90 minutes after administration. Concomitant use of lasmiditan and CNS depressants has not been studied clinically. MANAGEMENT: Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation. Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered. References "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Professional:MONITOR: Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions. Patients treated with lasmiditan are at risk of CNS depression, including dizziness and sedation, as well as driving impairment. In clinical studies, dizziness and sedation were reported in up to 17% and 7%, respectively, of patients receiving lasmiditan, and dizziness was the most common adverse event resulting in discontinuation (greater than 2%). In a computer-based driving study, a significant, dose-dependent impairment of subjects' ability to drive was observed with single 50, 100, and 200 mg lasmiditan doses at 90 minutes after administration. Concomitant use of lasmiditan and CNS depressants has not been studied clinically.
MANAGEMENT: Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation. Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.
- "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: promethazine
Brand name: Phenergan, Phenadoz, Promethegan
Synonyms: Phenergan
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lasmiditan-Phenergan injection
- Lasmiditan-Phenergan Injection, Intravenous
- Lasmiditan-Phenergan Rectal
- Lasmiditan-Phenergan Suppositories
- Lasmiditan-Phenergan VC
- Lasmiditan-Phenergan w/Codeine
- Phenergan (Promethazine Tablets)-Latanoprost
- Phenergan (Promethazine Tablets)-Latanoprost and netarsudil ophthalmic
- Phenergan (Promethazine Tablets)-Latanoprost and Timolol
- Phenergan (Promethazine Tablets)-Latanoprost Eye Drops (Emulsion)
- Phenergan (Promethazine Tablets)-Latanoprost Eye Drops (Solution)
- Phenergan (Promethazine Tablets)-Latanoprost ophthalmic